Please login to the form below

Not currently logged in
Email:
Password:

GSK announces combination approval for Avodart

GlaxoSmithKline has announced that the US Food and Drug Administration has approved Avodart in combination with tamsulosin (Flomax) for the treatment of symptomatic enlarged prostate
GlaxoSmithKline (GSK) has announced that the US Food and Drug Administration (FDA) has approved Avodart in combination with tamsulosin (Flomax) for the treatment of symptomatic enlarged prostate.

Half of all men over 50 years old are affected by enlarged prostate. The two-year study into the use of Avodart combined with tamsulosin showed that in combination the medicines were more effective than single drug therapies at treating common symptoms such as nocturia.

Both drugs already have FDA approval for use singularly in the treatment of enlarged prostate. "The combination of Avodart and tamsulosin at diagnosis allows doctors to simultaneously treat the patient's prostate on two fronts by reducing prostate size and rapidly improving symptoms," said Dr Steven A Kaplan, from Weill Cornell Medical College of Cornell University in New York City.

The randomised, double-blind study of the combination of Avodart and tamsulosin is one of the largest clinical trials to date involving men with enlarged prostate. It was the first long term assessment of the combination of Avodart, which works by suppressing the male hormone responsible for the enlargement of the prostate, and an alpha-blocker.

23rd June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics